Abstract

At the beginning of the 21st century, fibromyalgia syndrome (FM) has become a diagnostic category that includes extremely large numbers of people, predominantly women. Estimates that perhaps 2 to 4% of the adult population suffer from FM have been widely accepted. Moreover, patients diagnosed with FM have incurred substantial medical costs, to say nothing about high rates of disability. Yet the diagnosis has remained highly contested, and there are competing etiological theories and therapies. Indeed, a leading authority has identified what he calls the "fibromyalgia wars" (Wolfe 2009). To some, the syndrome is "an age-old malady begging for respect" (Powers 1993). To others, it is a form of "labeling woefulness" ..